Nuvation Bio Inc.
NUVB$522.74B
Mega CapNYSEPharmaceutical Preparations🇺🇸North AmericaNEW YORK
Drugs in Pipeline
5
Phase 3 Programs
3
Upcoming Catalysts
2
Next Catalyst
Oct 1, 2026
26wMarket Overview
Stock performance and key metrics
NUVB News
Catalyst Timeline
2 upcoming, 1 past
Drug Pipeline
Taletrectinib
Non Small Cell Lung Cancer
Crizotinib
Non Small Cell Lung Cancer
safusidenib
Glioma
NUV-1511
Advanced Solid Tumor
AB-106
Non Small Cell Lung Cancer
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Taletrectinib | Phase 3 | Non Small Cell Lung Cancer | - | - |
Crizotinib | Phase 3 | Non Small Cell Lung Cancer | - | - |
safusidenib | Phase 3 | Glioma | - | - |
NUV-1511 | Phase 2 | Advanced Solid Tumor | - | - |
AB-106 | Phase 2 | Non Small Cell Lung Cancer | - | - |
Regulatory Approvals
Data is aggregated from public sources (FDA, SEC, ClinicalTrials.gov). While we strive for accuracy, information may be incomplete, delayed, or contain errors. Terms apply